Perspective Therapeutics (CATX) Competitors $3.68 +0.12 (+3.37%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.60 -0.08 (-2.20%) As of 08/22/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX vs. PLSE, MDXG, INMD, IRMD, KMTS, EMBC, BBNX, TNDM, AXGN, and SIBNShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Pulse Biosciences (PLSE), MiMedx Group (MDXG), InMode (INMD), iRadimed (IRMD), Kestra Medical Technologies (KMTS), Embecta (EMBC), Beta Bionics (BBNX), Tandem Diabetes Care (TNDM), AxoGen (AXGN), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Its Competitors Pulse Biosciences MiMedx Group InMode iRadimed Kestra Medical Technologies Embecta Beta Bionics Tandem Diabetes Care AxoGen SiBone Perspective Therapeutics (NYSE:CATX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Do institutionals and insiders hold more shares of CATX or PLSE? 54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CATX or PLSE? In the previous week, Perspective Therapeutics had 20 more articles in the media than Pulse Biosciences. MarketBeat recorded 21 mentions for Perspective Therapeutics and 1 mentions for Pulse Biosciences. Perspective Therapeutics' average media sentiment score of 0.68 beat Pulse Biosciences' score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perspective Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CATX or PLSE more profitable? Pulse Biosciences has a net margin of 0.00% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Pulse Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% Pulse Biosciences N/A -63.19%-54.98% Which has more volatility and risk, CATX or PLSE? Perspective Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Which has stronger earnings and valuation, CATX or PLSE? Perspective Therapeutics has higher earnings, but lower revenue than Pulse Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective TherapeuticsN/AN/A-$46.51MN/AN/APulse Biosciences$700K1,638.75-$53.58M-$1.05-16.24 Do analysts recommend CATX or PLSE? Perspective Therapeutics currently has a consensus price target of $12.56, suggesting a potential upside of 241.18%. Pulse Biosciences has a consensus price target of $22.00, suggesting a potential upside of 29.03%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Perspective Therapeutics is more favorable than Pulse Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Pulse Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPerspective Therapeutics beats Pulse Biosciences on 9 of the 14 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$273.29M$85.46M$5.76B$20.92BDividend YieldN/AN/A4.41%3.58%P/E RatioN/A11.0031.1029.13Price / SalesN/A105.21432.5153.02Price / CashN/A18.4137.7323.54Price / Book1.387.139.535.45Net Income-$46.51M-$26.48M$3.26B$992.10M7 Day Performance1.94%-1.01%2.10%2.61%1 Month Performance-15.40%-3.56%2.81%1.46%1 Year Performance-76.56%57.70%30.56%10.72% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics1.58 of 5 stars$3.68+3.4%$12.56+241.2%-75.4%$273.29MN/A0.0070Analyst RevisionPLSEPulse Biosciences3.5376 of 5 stars$15.68-3.0%$22.00+40.3%-20.8%$1.09B$700K-14.93140MDXGMiMedx Group3.2618 of 5 stars$7.19+1.1%$12.00+66.9%+11.1%$1.05B$348.88M34.24870Positive NewsINMDInMode1.9906 of 5 stars$14.31-0.3%$18.04+26.1%-4.4%$907.05M$394.82M5.79480Positive NewsIRMDiRadimed4.6421 of 5 stars$70.11-0.4%$72.00+2.7%+62.5%$895.23M$73.24M43.28110Positive NewsKMTSKestra Medical TechnologiesN/A$16.09+0.2%$27.33+69.9%N/A$824.15M$59.81M0.00300EMBCEmbecta4.8382 of 5 stars$13.48-1.5%$19.00+40.9%+9.0%$800.66M$1.12B9.432,100Positive NewsBBNXBeta Bionics2.6296 of 5 stars$17.26+1.3%$22.56+30.7%N/A$740.73M$65.12M0.00294News CoveragePositive NewsInsider TradeTNDMTandem Diabetes Care4.6054 of 5 stars$10.84+0.2%$22.67+109.1%-71.9%$731.10M$940.20M-3.512,650Analyst ForecastAXGNAxoGen3.017 of 5 stars$15.49+3.8%$26.00+67.9%+31.7%$686.97M$187.34M-154.88450Short Interest ↑SIBNSiBone4.1755 of 5 stars$15.54+0.5%$23.67+52.3%+10.0%$666.96M$167.18M-27.75350News CoverageInsider Trade Related Companies and Tools Related Companies PLSE Alternatives MDXG Alternatives INMD Alternatives IRMD Alternatives KMTS Alternatives EMBC Alternatives BBNX Alternatives TNDM Alternatives AXGN Alternatives SIBN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access